NO942959L - Insulinpreparat - Google Patents

Insulinpreparat

Info

Publication number
NO942959L
NO942959L NO942959A NO942959A NO942959L NO 942959 L NO942959 L NO 942959L NO 942959 A NO942959 A NO 942959A NO 942959 A NO942959 A NO 942959A NO 942959 L NO942959 L NO 942959L
Authority
NO
Norway
Prior art keywords
insulin
formulation
zinc
total
present
Prior art date
Application number
NO942959A
Other languages
English (en)
Other versions
NO942959D0 (no
Inventor
James Arthur Hoffmann
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO942959D0 publication Critical patent/NO942959D0/no
Publication of NO942959L publication Critical patent/NO942959L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Insullnpreparat omfattende en suspensjon av Ultralente- krystaller og en total slnkkonsentrasjon i preparatet fra ca 0,5 mg til ca 20 mg per 100 enheter Insulin. Over 50 * av den totale sinken l preparatet befinner seg i den oppløselige fraksjonen i steden for i kompleks med insulinet. Dette insulinpreparatet har generelt en pH-verdi fra ca 6,0 til ca 7,4. I tillegg Inneholder insulinpreparatet ikke andre proteiner slik som protamln. Det sinkmodlfiserte preparatet utviser egenskaper for et meget lengevirkende humaninsulinpro- dukt.
NO942959A 1993-08-13 1994-08-09 Insulinpreparat NO942959L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/106,106 US5534488A (en) 1993-08-13 1993-08-13 Insulin formulation

Publications (2)

Publication Number Publication Date
NO942959D0 NO942959D0 (no) 1994-08-09
NO942959L true NO942959L (no) 1995-02-14

Family

ID=22309529

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942959A NO942959L (no) 1993-08-13 1994-08-09 Insulinpreparat

Country Status (27)

Country Link
US (1) US5534488A (no)
EP (1) EP0646379B1 (no)
JP (1) JPH07149660A (no)
KR (1) KR950005324A (no)
CN (1) CN1109364A (no)
AT (1) ATE207761T1 (no)
AU (1) AU674975B2 (no)
BR (1) BR9403204A (no)
CA (1) CA2129763A1 (no)
CO (1) CO4230235A1 (no)
CZ (1) CZ193794A3 (no)
DE (1) DE69428860T2 (no)
DK (1) DK0646379T3 (no)
ES (1) ES2164691T3 (no)
HU (1) HUT67853A (no)
IL (1) IL110581A0 (no)
NO (1) NO942959L (no)
NZ (1) NZ264197A (no)
PE (1) PE14495A1 (no)
PH (1) PH30757A (no)
PL (1) PL177002B1 (no)
PT (1) PT646379E (no)
RU (1) RU2135205C1 (no)
TW (1) TW326394B (no)
UA (1) UA27874C2 (no)
YU (1) YU50494A (no)
ZA (1) ZA945939B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578238A (en) * 1992-10-30 1996-11-26 Lord Corporation Magnetorheological materials utilizing surface-modified particles
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
EP1396272A1 (en) * 1997-12-23 2004-03-10 Eli Lilly & Company Insoluble Insulin Compositions for Controlling Blood Glucose
US6956021B1 (en) * 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
WO2001000675A1 (en) * 1999-06-29 2001-01-04 Eli Lilly And Company Protamine-free insoluble acylated insulin compositions
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
CA2402191C (en) * 2000-03-24 2012-03-13 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
US7227033B2 (en) 2002-01-09 2007-06-05 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
WO2002029833A1 (en) * 2000-10-06 2002-04-11 The Adviser - Defence Research & Development Organisation A magneto sensitive fluid composition and a process for preparation thereof
EP1344229B1 (en) * 2000-11-29 2008-03-05 The Adviser Defence Research & Development Organisation, Ministry of Defence, Government of India A magnetorheological fluid composition and a process for preparation thereof
IL156435A0 (en) * 2001-02-09 2004-01-04 Genentech Inc Crystallization of igf-1
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
RU2251426C1 (ru) * 2003-09-18 2005-05-10 Цыганков Владимир Владимирович Способ получения инсулина из природного источника и инсулин
AU2005209199B2 (en) * 2004-01-16 2008-09-11 Biodel Inc. Sublingual drug delivery device
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
DE602005014962D1 (de) * 2004-03-12 2009-07-30 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
CN102001962B (zh) 2004-05-06 2013-04-03 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
AU2005249410A1 (en) * 2004-05-14 2005-12-15 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
BRPI0513508B1 (pt) 2004-07-19 2021-06-01 Biocon Limited Conjugados de insulina-oligômero, formulações e usos desses
CN101014360A (zh) 2004-08-03 2007-08-08 埃米斯菲尔技术公司 抗糖尿病口服胰岛素－双胍组合物
WO2006124047A2 (en) * 2004-08-13 2006-11-23 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
RU2288000C1 (ru) * 2005-04-27 2006-11-27 Институт нефтехимического синтеза им. А.В. Топчиева РАН (ИНХС РАН) Раствор инсулина для перорального введения
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
WO2007121256A2 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
ES2841379T3 (es) 2007-03-13 2021-07-08 Jds Therapeutics Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
JP5868594B2 (ja) 2007-10-16 2016-02-24 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ 経口投与可能な固形医薬組成物及びそのプロセス
US20090175840A1 (en) * 2008-01-04 2009-07-09 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
PL2451437T3 (pl) 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
CN102770153B (zh) * 2010-02-22 2014-05-07 卡斯西部储备大学 呈可溶和结晶形式的长效胰岛素类似物制剂
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
AU2012223282B2 (en) 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CA3014308A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
US2882202A (en) * 1950-04-05 1959-04-14 Novo Terapeutisk Labor As Insulin crystal preparations and methods of producing them
US2882203A (en) * 1951-06-26 1959-04-14 Novo Terapeutisk Labor As Injectable insulin preparation with protracted effect
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US2819999A (en) * 1953-11-13 1958-01-14 Novo Terapeutisk Labor As Process for crystallization of insulin using freeze dried insulin as seeding material
US2799622A (en) * 1953-11-14 1957-07-16 Novo Terapeutisk Labor As Process of producing insulin crystals of substantially uniform size and compositions thereof
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
DE3101382A1 (de) * 1981-01-17 1982-09-02 Hoechst Ag, 6000 Frankfurt "verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
SU1131507A1 (ru) * 1982-05-28 1984-12-30 Черновицкий Ордена Трудового Красного Знамени Государственный Университет Способ получени инсулина
DE3511269A1 (de) * 1985-04-12 1986-10-09 Veb Berlin-Chemie, Ddr 1199 Berlin Verfahren zur reinigung von insulin
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus

Also Published As

Publication number Publication date
PT646379E (pt) 2002-03-28
CO4230235A1 (es) 1995-10-19
DE69428860T2 (de) 2002-05-02
EP0646379B1 (en) 2001-10-31
CZ193794A3 (en) 1995-03-15
JPH07149660A (ja) 1995-06-13
CA2129763A1 (en) 1995-02-14
PL177002B1 (pl) 1999-09-30
RU2135205C1 (ru) 1999-08-27
DE69428860D1 (de) 2001-12-06
KR950005324A (ko) 1995-03-20
NZ264197A (en) 1997-01-29
AU7024794A (en) 1995-02-23
ZA945939B (en) 1996-02-08
BR9403204A (pt) 1995-04-18
US5534488A (en) 1996-07-09
AU674975B2 (en) 1997-01-16
HUT67853A (en) 1995-05-29
ATE207761T1 (de) 2001-11-15
PH30757A (en) 1997-10-17
DK0646379T3 (da) 2001-12-03
YU50494A (sh) 1997-01-08
PE14495A1 (es) 1995-06-02
TW326394B (en) 1998-02-11
CN1109364A (zh) 1995-10-04
PL304600A1 (en) 1995-02-20
HU9402287D0 (en) 1994-09-28
IL110581A0 (en) 1994-11-11
UA27874C2 (uk) 2000-10-16
ES2164691T3 (es) 2002-03-01
NO942959D0 (no) 1994-08-09
EP0646379A1 (en) 1995-04-05

Similar Documents

Publication Publication Date Title
DK0646379T3 (da) Insulinformulering
CY1646A (en) Use of n-(4-phenoxy-2,6-diisopropylphenyl)-n'-tert.butylthiourea in the control of white flies
AU2173988A (en) Stabilised human protein preparations
NO912281L (no) Isoformer av erythropoietin.
GB9108652D0 (en) Immunoreactive compounds
CA2113995A1 (en) Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins
WO1994001006A3 (en) Composition for use as a food or food supplement
CA2015186A1 (en) Nutrient composition
AU8188087A (en) Variants of hirudin, their use and their preparation
GR3034309T3 (en) IFN--g(b) LIQUID FORMULATIONS
AU6406590A (en) Porcine lactoferrin amino acid and cdna sequence
AU8375891A (en) Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same
MD1714G2 (ro) Compoziţie terapeutică în formă de sirop, conţinând N-acetilcisteină
EP0508435A3 (en) Pharmaceutical composition of stabilized (leu 13)-motilin-hse
ATE262307T1 (de) Verwendung von goldlegierungen für konstruktionselemente in der dentaltechnik
CA2153071A1 (en) Derivatized calcitonins
GR3007486T3 (no)
EP0300741A3 (en) Human thymopoietin
EP0292302A3 (en) Human splenin
CA2247998A1 (en) Fragments of cr1 and their use
TH17521A (th) สูตรผสมอินซูลิน

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application